Awardee OrganizationNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Description
Abstract Text
A vaccine against Ebola virus would be highly significant in preventing outbreaks which are both naturally occurring or the result of bioterrorist activity. Modifications to previously developed Ebola vaccines were made during the past year to improve expression and immunogenicity.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
UEI
Project Start Date
Project End Date
Budget Start Date
Budget End Date
Project Funding Information for 2006
Total Funding
Direct Costs
Indirect Costs
Sub Projects
No Sub Projects information available for 1Z01AI005079-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1Z01AI005079-02
Patents
No Patents information available for 1Z01AI005079-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1Z01AI005079-02
Clinical Studies
No Clinical Studies information available for 1Z01AI005079-02
News and More
Related News Releases
No news release information available for 1Z01AI005079-02
History
No Historical information available for 1Z01AI005079-02
Similar Projects
No Similar Projects information available for 1Z01AI005079-02